| Bioactivity | VEGFR-2-IN-58 (Compound 7b) inhibits VEGFR-2 with an IC50 of 42.5 nM. VEGFR-2-IN-58 displays selective cytotoxicity against cancer cells. VEGFR-2-IN-58 shows cellular growth arrest at the G2/M phase in cancer cells. VEGFR-2-IN-58 induces cancer cells Apoptosis, increasing BAX expression and reducing Bcl2 expression. VEGFR-2-IN-58 inhibits wound closure in cancer cells[1]. |
| Invitro | VEGFR-2-IN-58 抑制HepG2, MCF-7, A549, HT-29, PC3 和 WI-38 细胞增殖, 其 IC50 分别为 7.28, 6.72, 6.66, 8.51, 14.5, 30 μM[1]。VEGFR-2-IN-58 (8.51 μM, 24 h) 在 HT-29 细胞系中除了诱导凋亡外，还表现出 G2/M 期细胞生长抑制[1]。VEGFR-2-IN-58 (0.85, 4.26 μM, 48 h) 在 HT-29 细胞中展现出对伤口愈合抑制显著[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> VEGFR-2-IN-58 相关抗体: Western Blot Analysis[1] Cell Line: |
| Formula | C24H16ClN3O |
| Molar Mass | 397.86 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Abd El-Haleem AH, et al. Furan- and Furopyrimidine-Based Derivatives: Synthesis, VEGFR-2 Inhibition, and In Vitro Cytotoxicity. ACS Med Chem Lett. 2024 Nov 25;15(12):2150-2157. |